home.aspx

 
.

USING REFERENCE STANDARDS TO VALIDATE YOUR NGS ONCOLOGY WORKFLOW

SHARESHARESHARE
We are currently at an exciting precipice in clinical oncology management, where an increased rate of biomarker identification is driving the development of new targeted therapies, coupled with advances in sequencing technology capability. In the latest version release of COSMIC (v85) there are now 719 cancer-associated genes listed in the Cancer Gene Census, and in 2017 35% of the new molecular entities (NMEs) approved by the FDA were precision medicines. As a result, we are seeing larger and more complex gene panels being designed by assay developers to support the clinical community in testing for actionable mutations in these genes. This now includes more challenging variant types such as CNVs, INDELs and gene fusions.